Compare Motorola Solutions Inc (MSI) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Motorola Solutions Inc vs Viatris Inc — how do they compare? Motorola Solutions Inc trades at $445.6 (market cap $74.00B), while Viatris Inc trades at $17.41 (market cap $20.03B). The key difference: Motorola Solutions Inc is far larger — about 3.7× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Motorola Solutions Inc for 100 Days and Viatris Inc for 57 Days on average.
| MSI | VTRS | |
|---|---|---|
Market Cap | $74.00B | $20.03B |
Volume | 722,147 | 14,109,977 |
Sector | Technology | Health |
52-Week High | $491.24 | $18.27 |
52-Week Low | $363.83 | $9.74 |
Typical Hold Time | 100 Days | 57 Days |
Enterprise Value | $82.90B | $32.15B |
Dividend Yield | 1.08% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Motorola Solutions (MSI) trades at $448.48, down 1.72% on the day, amid a bearish technical signal. The company shows strong fundamentals with revenue growth to $11.68B in 2025 and a record $15.6B backlog. Recent acquisitions like D-Fend Solutions and a $139M Louisiana public safety contract highlight expansion in security and AI-driven solutions. Earnings have consistently beaten estimates, with Q2 2026 EPS of $4.41 surpassing the $3.85 expectation. However, cash flow trends show significant investing outflows for growth initiatives.
The outlook remains positive given analyst consensus with a $525.86 price target and 70.59% buy ratings, though risks include high valuation multiples and increased debt levels from acquisitions. The stock's current bearish technical stance may present a buying opportunity if fundamentals continue to strengthen, but investors should monitor cash flow sustainability and integration of recent purchases.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.
Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Motorola Solutions Inc
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
